| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/16/1999 | DE19909757A1 Water-soluble or -dispersible comb polymers used in hair cosmetics, e.g. hair spray, lacquer, setting foam or styling gel |
| 09/16/1999 | DE19810999A1 Use of sphingosine compounds to treat inflammatory skin disorders, especially psoriasis, acne and dermatoheliosis |
| 09/16/1999 | DE19810012A1 Kosmetische und/oder pharmazeutische Zubereitungen Cosmetic and / or pharmaceutical preparations |
| 09/16/1999 | DE19731591C2 Pharmazeutische Mittel enthaltend perfluoralkylgruppenhaltige Trijodaromaten und ihre Verwendung in der Tumortherapie und interventionellen Radiologie Pharmaceutical preparations containing perfluoroalkyl Trijodaromaten and their use in cancer therapy and interventional radiology |
| 09/16/1999 | CA2683097A1 Novel opiate compounds, methods of making and methods of use |
| 09/16/1999 | CA2601285A1 Agents for use in the treatment of amyloidosis |
| 09/16/1999 | CA2575850A1 The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation |
| 09/16/1999 | CA2332114A1 Novel delivery of hydroxy carboxylic acids |
| 09/16/1999 | CA2327329A1 Cholesterol recognition sequence |
| 09/16/1999 | CA2323496A1 Enzyme inhibitors |
| 09/16/1999 | CA2323493A1 Modulators of protein tyrosine phosphatases (ptpases) |
| 09/16/1999 | CA2323490A1 inhibition of angiogenesis |
| 09/16/1999 | CA2323472A1 Modulators of protein tyrosine phosphatases |
| 09/16/1999 | CA2323456A1 Benzofurylpyrone derivatives |
| 09/16/1999 | CA2323451A1 Skin conditioner |
| 09/16/1999 | CA2323448A1 Methods of inhibiting bone resorption |
| 09/16/1999 | CA2323443A1 Ige antibody production inhibitors and autoimmune diseases inhibitors |
| 09/16/1999 | CA2323210A1 Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| 09/16/1999 | CA2323208A1 Vitronectin receptor antagonists |
| 09/16/1999 | CA2323199A1 Use of corneal hardening agents in enzyme orthokeratology |
| 09/16/1999 | CA2323177A1 Composition |
| 09/16/1999 | CA2323109A1 Ribozymes capable of inhibiting the expression of the ccr5 receptor |
| 09/16/1999 | CA2323089A1 Inhibitors of type 5 and type 3 17.beta.-hydroxysteroid dehydrogenase and methods for their use |
| 09/16/1999 | CA2323016A1 Multicomponent complex for use with a substrate |
| 09/16/1999 | CA2323015A1 Remedies for aids |
| 09/16/1999 | CA2322962A1 Phenanthrofuran derivatives |
| 09/16/1999 | CA2322873A1 Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors |
| 09/16/1999 | CA2322848A1 Novel methods for treating disorders in which docosahexaenoic acid (dha) levels are effected |
| 09/16/1999 | CA2322824A1 Combination therapy and composition for acute coronary ischemic syndrome and related conditions |
| 09/16/1999 | CA2322743A1 Fibrinogen receptor antagonists |
| 09/16/1999 | CA2322503A1 Disposable absorbent article having a skin care composition containing an enzyme inhibitor |
| 09/16/1999 | CA2322494A1 Novel nucleoside analogs and uses in treating disease |
| 09/16/1999 | CA2322232A1 Lyophilized polynucleotide composition, method of preparation, and uses thereof |
| 09/16/1999 | CA2322165A1 Monoterpenoid derivatives for treatment of cancer |
| 09/16/1999 | CA2321935A1 Use of alpha-rar antagonists for inhibition of mucin secretion |
| 09/16/1999 | CA2321834A1 Amino anthracyclinone derivatives and their use in the treatment of amyloidosis |
| 09/16/1999 | CA2321832A1 Heterocyclyl anthracyclinone derivatives |
| 09/16/1999 | CA2321216A1 Lipid compounds derived from sphingoid bases, preparation method and uses in cosmetics and dermopharmacy |
| 09/16/1999 | CA2320718A1 Lipoic acid analogs |
| 09/16/1999 | CA2319765A1 New contraceptive kit |
| 09/16/1999 | CA2288240A1 Methods and compositions for delivery of taxanes |
| 09/15/1999 | EP0942001A1 Sphingoid Lipid Compounds, a Process for Their Production and Cosmetic and Dermopharmaceutical uses Thereof |
| 09/15/1999 | EP0942000A2 2'Modified oligonucleotides |
| 09/15/1999 | EP0941999A2 Preparation of azithromycin dihydrate |
| 09/15/1999 | EP0941998A2 3,6-ketal and enol ether macrolide antibiotics |
| 09/15/1999 | EP0941994A1 Pyrazolopyrimidines and pyrazolotriazines with 5-HT6 receptor affinity |
| 09/15/1999 | EP0941992A1 Ipriflavone preparation process |
| 09/15/1999 | EP0941991A1 2,4-Bis (4-amidino)phenyl furans as anti-pneumocystis carinii agents |
| 09/15/1999 | EP0941981A1 Cyclopentenones, process for preparing the same, and the use thereof |
| 09/15/1999 | EP0941738A1 Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria |
| 09/15/1999 | EP0941737A1 Apoptosis inducers |
| 09/15/1999 | EP0941733A2 Methods of inhibiting leaderless protein export using cardiac glycosides and derivatives |
| 09/15/1999 | EP0941356A2 Stabilized transient gene expression |
| 09/15/1999 | EP0941342A1 Human squalene epoxidase |
| 09/15/1999 | EP0941328A1 Human breast tumor-specific proteins |
| 09/15/1999 | EP0941319A1 Peptides capable of inhibiting the endocytosis of the app and corresponding nucleotide sequences |
| 09/15/1999 | EP0941253A1 New butyric esters with antiproliferative activity and the pharmaceutical compositions containing them |
| 09/15/1999 | EP0941252A1 Anti-p53 single-chain antibody fragments and their uses |
| 09/15/1999 | EP0941245A1 Promoter for smooth muscle cell expression |
| 09/15/1999 | EP0941243A1 Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use |
| 09/15/1999 | EP0941229A1 Purification of fermented clavulanic acid |
| 09/15/1999 | EP0941227A1 Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents |
| 09/15/1999 | EP0941226A1 (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors |
| 09/15/1999 | EP0941225A1 Piperidine derivatives |
| 09/15/1999 | EP0941224A1 Multivalent salts of pyridostigmine and related compounds |
| 09/15/1999 | EP0941223A1 Certain pyrazole derivatives as corticotropin-releasing factor receptor crf1 specific ligands |
| 09/15/1999 | EP0941221A1 Substituted dihydrobenzofurans as pde inhibitors |
| 09/15/1999 | EP0941218A1 Antithrombotic organic nitrates |
| 09/15/1999 | EP0941124A1 Antisense oligonucleotide compositions for selectively killing cancer cells |
| 09/15/1999 | EP0941122A2 Compositions and methods for polynucleotide delivery |
| 09/15/1999 | EP0941121A2 Stable lyophilized pharmaceutical substances from monoclonal or polyclonal antibodies |
| 09/15/1999 | EP0941116A2 Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device |
| 09/15/1999 | EP0941115A1 Use of growth hormone or a growth hormone secretagogue for promoting bone formation |
| 09/15/1999 | EP0941113A1 Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors |
| 09/15/1999 | EP0941112A1 Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors |
| 09/15/1999 | EP0941108A1 Wound healing and treatment of fibrosis |
| 09/15/1999 | EP0941100A2 Pharmaceutical compositions containing lamivudine and zidovudine |
| 09/15/1999 | EP0941099A1 Method of treating bronchitis with uridine triphosphates and related compounds |
| 09/15/1999 | EP0941098A1 Method for inhibiting desoxyribonucleotide triphosphate biosynthesis |
| 09/15/1999 | EP0941097A1 Use of mixtures of active substances for the production of hypocholesteremic agents |
| 09/15/1999 | EP0941096A2 A method for lowering plasma levels of lipoprotein(a) |
| 09/15/1999 | EP0941095A1 Improved pharmaceutical compositions |
| 09/15/1999 | EP0941094A1 Process for manufacturing ophthalmic suspensions |
| 09/15/1999 | EP0941093A1 Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety |
| 09/15/1999 | EP0941092A1 Use of nk-1 receptor antagonists for treating major depressive disorders |
| 09/15/1999 | EP0941091A1 Composition, for the treatment of asthma, containing loratadine and a decongestant |
| 09/15/1999 | EP0941090A1 Pharmaceutical compositions containing n-sulphonyl indolin derivatives |
| 09/15/1999 | EP0941089A2 Compositions and methods for treating or preventing inflammatory diseases |
| 09/15/1999 | EP0941088A1 Use of conjugated linoleic acid to enhance natural killer lymphocyte function |
| 09/15/1999 | EP0941087A1 Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections |
| 09/15/1999 | EP0941086A1 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| 09/15/1999 | EP0941085A2 Formulation for electrically assisted delivery of lidocaine and epinephrine |
| 09/15/1999 | EP0941084A1 Raf kinase inhibitors |
| 09/15/1999 | EP0941083A1 Pharmaceutical compositions containing 3-iodo-1,2-propanediol having mucolytic activity |
| 09/15/1999 | EP0941082A2 New use for 1,3-propanediol derivatives |
| 09/15/1999 | EP0941081A2 New use of creatine |
| 09/15/1999 | EP0941080A2 Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents |
| 09/15/1999 | EP0941074A1 Delayed delivery system for acid-sensitive drugs |
| 09/15/1999 | EP0941067A2 Stable glassy state powder formulations |
| 09/15/1999 | EP0941065A1 Ionophore-mediated liposome loading of weakly basic drug |